Literature DB >> 16052402

Exogenous vascular endothelial growth factor can induce preeclampsia-like symptoms in pregnant mice.

Yusuke Murakami1, Takao Kobayashi, Kohei Omatsu, Mika Suzuki, Ryota Ohashi, Toshiki Matsuura, Motoi Sugimura, Naohiro Kanayama.   

Abstract

It is reported that expression of vascular endothelial growth factor (VEGF) in trophoblasts increases in cases with preeclampsia. Recently, we demonstrated that the lack of cyclin-dependent kinase inhibitor, p57kip2, expression in the fetus and the placenta plays a role in the development of preeclampsia-like symptoms in pregnant mice. Furthermore, we observed that VEGF mRNA and protein levels, especially VEGF (164), were higher and its expression was stronger in placentas of p57kip2-null embryos than in placentas of wild-type embryos. In this study we investigated whether exogenous murine VEGF (164) induced preeclampsia-like symptoms in pregnant mice, and anti-VEGF neutralized antibody could suppress these symptoms. Administration of VEGF induced hypercoagulation in the placental circulation and a significant elevation of systolic blood pressure in pregnant mice. Furthermore, we demonstrated that treatment with anti-VEGF antibody could suppress the hypercoagulability in placenta and the elevation of systolic blood pressure. These data suggest that VEGF is related to the pathophysiology of preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16052402     DOI: 10.1055/s-2005-872437

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  6 in total

1.  Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications.

Authors:  Xiujun Fan; Anshita Rai; Neeraja Kambham; Joyce F Sung; Nirbhai Singh; Matthew Petitt; Sabita Dhal; Rani Agrawal; Richard E Sutton; Maurice L Druzin; Sanjiv S Gambhir; Balamurali K Ambati; James C Cross; Nihar R Nayak
Journal:  J Clin Invest       Date:  2014-10-20       Impact factor: 14.808

2.  VEGF-A and VEGFR1 SNPs associate with preeclampsia in a Philippine population.

Authors:  Melissa D Amosco; Van Anthony M Villar; Justin Michael A Naniong; Lara Marie G David-Bustamante; Pedro A Jose; Cynthia P Palmes-Saloma
Journal:  Clin Exp Hypertens       Date:  2016-09-26       Impact factor: 1.749

3.  Vascular endothelial growth factor acts through novel, pregnancy-enhanced receptor signalling pathways to stimulate endothelial nitric oxide synthase activity in uterine artery endothelial cells.

Authors:  Mary A Grummer; Jeremy A Sullivan; Ronald R Magness; Ian M Bird
Journal:  Biochem J       Date:  2009-01-15       Impact factor: 3.857

Review 4.  Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.

Authors:  Samar Masoumi Moghaddam; Afshin Amini; David L Morris; Mohammad H Pourgholami
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

Review 5.  Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta.

Authors:  Manoj Kumar Jena; Neeta Raj Sharma; Matthew Petitt; Devika Maulik; Nihar Ranjan Nayak
Journal:  Biomolecules       Date:  2020-06-24

6.  Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia.

Authors:  Victoria L Bills; Julia Varet; Ann Millar; Steven J Harper; Peter W Soothill; David O Bates
Journal:  Clin Sci (Lond)       Date:  2009-02       Impact factor: 6.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.